In last trading session, Intellia Therapeutics, Inc. (NASDAQ:NTLA) saw 1,034,209 shares changing hands with its beta currently measuring 1.66. Company’s recent per share price level of $32.26 trading at -$1.97 or -5.76% at ring of the bell on the day assigns it a market valuation of $1.91 Billion. That closing price of NTLA’s stock is at a discount of -10.17% from its 52-week high price of $35.54 and is indicating a premium of 71.54% from its 52-week low price of $9.18. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 997.27 Million shares which gives us an average trading volume of 950.63 Million if we extend that period to 3-months.
For Intellia Therapeutics, Inc. (NTLA), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 2.1. Splitting up the data highlights that, out of 14 analysts covering the stock, none rated the stock as a Sell while 2 recommended an Overweight rating for the stock. 4 suggested the stock as a Hold whereas 8 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.61 in the current quarter.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) trade information
In the face of being in the red today for losing -5.76%, in the last five days NTLA remained trading in the green while hitting it’s week-highest on Wednesday, Nov 18 when the stock touched $35.54- price level, adding 9.23% to its value on the day. Intellia Therapeutics, Inc.’s shares saw a change of 119.9% in year-to-date performance and have moved 8.58% in past 5-day. Intellia Therapeutics, Inc. (NASDAQ:NTLA) showed a performance of 25.18% in past 30-days. Number of shares sold short was 12.89 Million shares which calculate 0.01 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $35.96 to the stock, which implies a rise of 11.47% to its current value. Analysts have been projecting $22 as a low price target for the stock while placing it at a high target of $57.5. It follows that stock’s current price would jump +78.24% in reaching the projected high whereas dropping to the targeted low would mean a loss of -31.8% for stock’s current value.
Intellia Therapeutics, Inc. (NTLA) estimates and forecasts
Statistics highlight that Intellia Therapeutics, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added +53.69% of value to its shares in past 6 months, showing an annual growth rate of 7.58% while that of industry is 14.4. Apart from that, the company came lowering its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to decline by -7% in the current quarter and calculating -19% decline in the next quarter. This year revenue growth is estimated to rise 53.5% from the last financial year’s standing.
11 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $14.09 Million for the same. And 7 analysts are in estimates of company making revenue of $11.56 Million in the next quarter that will end in March 01, 2021. Company posted $10.94 Million of sales in current quarter a year earlier. Analysts are expecting this quarter sales to grow by 28.8%.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -50.6% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -6.3% while estimates for its earnings growth in next 5 years are of 30%
Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s Major holders
Insiders are in possession of 16.63% of company’s total shares while institution are holding 87.4% percent of that, with stock having share float percentage of 104.84%. Investors also watch the number of corporate investors in a company very closely, which is 252 institutions for Intellia Therapeutics, Inc. that are currently holding shares of the company. ARK Investment Management, LLC is the top institutional holder at NTLA for having 11.4 Million shares of worth $226.73 Million. And as of September 29, 2020, it was holding 19.3% of the company’s outstanding shares.
The second largest institutional holder is Nikko Asset Management Americas, Inc., which was holding about 6.06 Million shares on September 29, 2020. The number of shares represents firm’s hold over 10.26% of outstanding shares, having a total worth of $120.52 Million.
On the other hand, ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF are the top two Mutual Funds which own company’s shares. As of July 30, 2020, the former fund manager was holding 6965670 shares of worth $124.06 Million or 11.79% of the total outstanding shares. The later fund manager was in possession of 2.48 Million shares on July 30, 2020, making its stake of worth around $44.16 Million in the company or a holder of 4.2% of company’s stock.